Triglycerides in Nonalcoholic Fatty Liver Disease: Guilty Until Proven Innocent.
Triglycerides in Nonalcoholic Fatty Liver Disease: Guilty Until Proven Innocent.
复制标题
DOI：
10.1016/j.tips.2020.12.001
复制
发表时间：
2021-03
影响因子：
13.8
通讯作者：
Biddinger, Sudha B.
中科院分区：
文献类型：
--
作者：
Semova, Ivana;Biddinger, Sudha B.
终末期肝病是非酒精性脂肪性肝病(NAFLD)的一种罕见但致命的并发症。在NAFLD中，胰岛素抵抗在临床上被定义为胰岛素维持血糖稳态的能力受损，与促进甘油三酯积累的胰岛素作用的扰动有关，例如增加新生脂肪生成。然而，终末期肝病发生发展的关键步骤不是甘油三酯的蓄积，而是肝细胞的损伤。甘油三酯是否以及如何促进肝细胞损伤仍不清楚。因此，很难预测旨在降低肝脏甘油三酯的药物是否能预防NAFLD最重要的并发症。
End-stage liver disease is a rare but fatal complication of non-alcoholic fatty liver disease (NAFLD). In NAFLD, insulin resistance, which is clinically defined as the impairment of insulin’s ability to maintain glucose homeostasis, is associated with perturbations in insulin action that promote triglyceride accumulation, such as increasing de novo lipogenesis. However, the key step in the development of end-stage liver disease is not the accumulation of triglycerides, but hepatocyte injury. Whether and how triglycerides promote hepatocyte injury remains unclear. Consequently, it is difficult to predict whether drugs designed to reduce hepatic triglycerides will prevent the most important complications of NAFLD.
登录
查看更多内容
影响因子：
13.5
作者：
Bril, Fernando;Barb, Diana;Cusi, Kenneth
通讯作者：
Cusi, Kenneth
影响因子：
13.5
作者：
DESCHAMPS, D;DEBECO, V;PESSAYRE, D
通讯作者：
PESSAYRE, D
影响因子：
29
作者：
Haas JT;Miao J;Chanda D;Wang Y;Zhao E;Haas ME;Hirschey M;Vaitheesvaran B;Farese RV Jr;Kurland IJ;Graham M;Crooke R;Foufelle F;Biddinger SB
通讯作者：
Biddinger SB
影响因子：
11.1
作者：
Dongiovanni P;Stender S;Pietrelli A;Mancina RM;Cespiati A;Petta S;Pelusi S;Pingitore P;Badiali S;Maggioni M;Mannisto V;Grimaudo S;Pipitone RM;Pihlajamaki J;Craxi A;Taube M;Carlsson LMS;Fargion S;Romeo S;Kozlitina J;Valenti L
通讯作者：
Valenti L
影响因子：
13.5
作者：
Gluchowski, Nina L.;Gabriel, Katlyn R.;Walther, Tobias C.
通讯作者：
Walther, Tobias C.